Glycyl-L-histidyl-L-lysine (GHK), commonly referred to as GHK tripeptide, is a naturally occurring peptide composed of the amino acids glycine, histidine, and lysine. It was first isolated from human plasma and is also found in saliva and urine. GHK is synthesized through standard peptide synthesis techniques, which involve the sequential addition of amino acids to form the tripeptide chain. Its structure allows it to bind copper ions, forming GHK-Cu, which is believed to be the active form in biological systems. Researchers have extensively studied GHK for its potential anti-aging and skin regenerative properties. It has been observed to enhance wound healing, improve skin elasticity, and reduce wrinkles. Additionally, GHK has been investigated for its role in modulating gene expression, influencing processes such as inflammation and tissue remodeling. The mechanism of action of GHK involves its ability to bind copper ions, which is crucial for its biological activity. It is thought to interact with cellular pathways that regulate gene expression, particularly those involved in tissue repair and anti-inflammatory responses. GHK may also influence the activity of metalloproteinases and other enzymes critical for skin health. Pharmacokinetic studies of GHK indicate that it has a relatively short half-life, with rapid degradation in biological systems. Its stability and bioavailability can vary depending on the route of administration, with limited data available for specific routes. Current research on GHK is ongoing, with studies exploring its broader therapeutic potential beyond dermatology. Regulatory agencies have not yet approved GHK as a medicinal product, and it is primarily available as a cosmetic ingredient or research chemical. Its legal status varies by country, and it remains under investigation for its safety and efficacy in clinical settings.